Verve Therapeutics (VERV) News Today $5.28 -0.12 (-2.22%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$5.52 +0.24 (+4.55%) As of 03/27/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Guggenheim Reiterates Buy Rating for Verve Therapeutics (NASDAQ:VERV)March 27 at 2:47 AM | americanbankingnews.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of "Buy" by AnalystsShares of Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) have earned an average rating of "Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price taMarch 26 at 12:38 PM | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Given "Buy" Rating at GuggenheimGuggenheim reiterated a "buy" rating on shares of Verve Therapeutics in a research note on Tuesday.March 26 at 10:32 AM | marketbeat.comVerve Therapeutics' (VERV) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Verve Therapeutics in a report on Tuesday.March 26 at 8:34 AM | marketbeat.comVerve Therapeutics' (VERV) Buy Rating Reiterated at HC WainwrightMarch 26 at 2:52 AM | americanbankingnews.comVerve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 CatalystsMarch 25 at 6:20 PM | seekingalpha.comWilliam Blair Remains a Buy on Verve Therapeutics (VERV)March 25 at 12:38 AM | markets.businessinsider.comVerve Therapeutics announces FDA clearance of IND application for VERVE-102March 24, 2025 | markets.businessinsider.comVerve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single DoseMarch 24, 2025 | globenewswire.comVerve Therapeutics (NASDAQ:VERV) Trading Down 6.2% - What's Next?Verve Therapeutics (NASDAQ:VERV) Shares Down 6.2% - Here's What HappenedMarch 19, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Down 11% - What's Next?Verve Therapeutics (NASDAQ:VERV) Stock Price Down 11% - Should You Sell?March 11, 2025 | marketbeat.comMutated DNA Restored to Normal in Gene Therapy AdvanceMarch 10, 2025 | nytimes.comWilliam Blair downgrades Neumora Therapeutics, Inc. (NMRA) to a HoldMarch 7, 2025 | markets.businessinsider.comVerve Therapeutics (NASDAQ:VERV) Shares Gap Down on Analyst DowngradeVerve Therapeutics (NASDAQ:VERV) Shares Gap Down Following Analyst DowngradeMarch 5, 2025 | marketbeat.comRoyal Bank of Canada Issues Pessimistic Forecast for Verve Therapeutics (NASDAQ:VERV) Stock PriceRoyal Bank of Canada reduced their target price on Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research report on Tuesday.March 5, 2025 | marketbeat.comVerve Therapeutics price target lowered to $15 from $17 at RBC CapitalMarch 4, 2025 | markets.businessinsider.comAnalysts Set Expectations for VERV Q1 EarningsVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - William Blair issued their Q1 2026 earnings per share (EPS) estimates for Verve Therapeutics in a note issued to investors on Thursday, February 27th. William Blair analyst M. Minter expects that the company will post earnings of ($0.77) perMarch 3, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright upped their price target on Verve Therapeutics from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday.March 1, 2025 | marketbeat.comVerve Therapeutics price target raised to $15 from $14 at H.C. WainwrightMarch 1, 2025 | markets.businessinsider.comVerve Therapeutics (NASDAQ:VERV) Releases Earnings Results, Beats Estimates By $0.14 EPSVerve Therapeutics (NASDAQ:VERV - Get Free Report) announced its earnings results on Thursday. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.14. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%.February 28, 2025 | marketbeat.comVerve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2February 28, 2025 | seekingalpha.comVerve Therapeutics Full Year 2024 Earnings: Beats ExpectationsFebruary 28, 2025 | finance.yahoo.comVertex ends gene editing research pact with VerveFebruary 27, 2025 | finance.yahoo.comVerve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025 | globenewswire.comWilliam Blair Reaffirms "Outperform" Rating for Verve Therapeutics (NASDAQ:VERV)William Blair restated an "outperform" rating on shares of Verve Therapeutics in a report on Friday.February 22, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Trading Down 6.7% - What's Next?Verve Therapeutics (NASDAQ:VERV) Stock Price Down 6.7% - Time to Sell?February 20, 2025 | marketbeat.comVerve Therapeutics (VERV) Expected to Announce Quarterly Earnings on TuesdayVerve Therapeutics (NASDAQ:VERV) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Up 10.4% - Here's What HappenedVerve Therapeutics (NASDAQ:VERV) Shares Up 10.4% - Here's WhyFebruary 15, 2025 | marketbeat.comNASDAQ:VERV (Verve Therapeutics, Inc.)February 13, 2025 | fool.caVerve Therapeutics (NASDAQ:VERV) Stock Price Down 4.9% - Time to Sell?Verve Therapeutics (NASDAQ:VERV) Stock Price Down 4.9% - What's Next?February 10, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Trading Up 6.7% - Here's What HappenedVerve Therapeutics (NASDAQ:VERV) Shares Up 6.7% - Here's WhyFebruary 5, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Shares Gap Up - What's Next?Verve Therapeutics (NASDAQ:VERV) Shares Gap Up - Should You Buy?February 4, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Trading Down 5.7% - Should You Sell?Verve Therapeutics (NASDAQ:VERV) Stock Price Down 5.7% - What's Next?February 3, 2025 | marketbeat.comKuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law FirmJanuary 31, 2025 | prnewswire.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Nisa Investment Advisors LLCNisa Investment Advisors LLC increased its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 465.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 42,781 shares of the company's stock after purchasing an additional 35January 30, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Up 5.6% - What's Next?Verve Therapeutics (NASDAQ:VERV) Trading Up 5.6% - Here's What HappenedJanuary 29, 2025 | marketbeat.comVerve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comVerve Therapeutics (NASDAQ:VERV) Trading Down 8.2% - Here's What HappenedVerve Therapeutics (NASDAQ:VERV) Trading Down 8.2% - Here's What HappenedJanuary 28, 2025 | marketbeat.comCompanies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In GrowthJanuary 27, 2025 | uk.finance.yahoo.comVerve Therapeutics (NASDAQ:VERV) Trading Up 6.1% - Should You Buy?Verve Therapeutics (NASDAQ:VERV) Trading 6.1% Higher - Should You Buy?January 24, 2025 | marketbeat.comCantor Fitzgerald Comments on VERV FY2025 EarningsVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Verve Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski aJanuary 23, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Up 6.1% - Here's What HappenedVerve Therapeutics (NASDAQ:VERV) Trading Up 6.1% - Time to Buy?January 22, 2025 | marketbeat.comEquities Analysts Offer Predictions for VERV FY2025 EarningsVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Verve Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski forecasts that the company will posJanuary 22, 2025 | marketbeat.comHow Advanced Drug Delivery is Revolutionizing Global Healthcare in 2025January 17, 2025 | baystreet.caVerve Therapeutics (NASDAQ:VERV) Trading 8.6% Higher - Time to Buy?Verve Therapeutics (NASDAQ:VERV) Trading Up 8.6% - Time to Buy?January 16, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Barclays PLCBarclays PLC grew its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 139.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 222,919 shares of the company's stock afJanuary 15, 2025 | marketbeat.comVerve Therapeutics announces anticipated 2025 milestonesJanuary 13, 2025 | markets.businessinsider.comVerve Therapeutics sees cash runway into mid-2027January 13, 2025 | markets.businessinsider.comVerve Therapeutics Announces Pipeline Progress and Anticipated 2025 MilestonesJanuary 13, 2025 | finance.yahoo.comVerve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | finance.yahoo.com Remove Ads Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address VERV Media Mentions By Week VERV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERV News Sentiment▼0.360.78▲Average Medical News Sentiment VERV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERV Articles This Week▼126▲VERV Articles Average Week Remove Ads Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcutis Biotherapeutics News Today Tarsus Pharmaceuticals News Today Harmony Biosciences News Today Travere Therapeutics News Today Janux Therapeutics News Today Disc Medicine News Today Agios Pharmaceuticals News Today Apogee Therapeutics News Today Mesoblast News Today Vera Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERV) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
